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Abstract 
Accumulating evidence points toward the antipsychotic potential of cannabidiol. However, the 
neurocognitive mechanisms underlying the antipsychotic effect of cannabidiol remain unclear. We 
investigated this in a double-blind, placebo-controlled, parallel-arm study. We investigated 33 
antipsychotic-naïve subjects at clinical high risk for psychosis (CHR) randomised to 600mg oral 
cannabidiol or placebo and compared them with 19 healthy controls. We used the monetary 
incentive delay task while participants underwent fMRI to study reward processing, known to be 
abnormal in psychosis. Reward and loss anticipation phases were combined to examine a 
motivational salience condition and compared with neutral condition. We observed abnormal 
activation in the left insula/parietal operculum in CHR participants given placebo compared to 
healthy controls associated with premature action initiation. Insular activation correlated with both 
positive psychotic symptoms and salience perception, as indexed by difference in reaction time 
between salient and neutral stimuli conditions. CBD attenuated the increased activation in the left 
insula/parietal operculum and was associated with overall slowing of reaction time, suggesting a 
possible mechanism for its putative antipsychotic effect by normalising motivational salience and 
moderating motor response.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 Introduction 
The aberrant salience hypothesis of psychosis (1) postulates that hyperdopaminergia in the 
mesostriatal pathway leads to aberrant assignment of salience to everyday experiences and stimuli, 
which in turn result in psychotic symptoms. Elevated presynaptic dopamine function in the striatum 
is established in psychotic disorders (2) and in subjects at clinical high risk for psychosis (CHR) (3, 4), 
and an understanding of the relationship between dopamine, aberrant salience and psychotic 
symptoms, particularly delusions, is emerging (5). It has been suggested that mesostriatal 
dopaminergic overactivity may be driven by glutamatergic dysfunction in the medial temporal lobe 
(MTL) (6), and both increased hippocampal blood flow (7) and metabolism (8) have been reported in 
CHR subjects and established psychosis.  
Dopamine signalling is fundamental to reward processing (9) which is dysfunctional in psychosis (10). 
Reward processing includes the attribution of ‘motivational salience’, whereby the anticipation of a 
rewarding stimulus or incentive prepares an individual for ‘approach behaviour’ toward eventual 
consumption. Neuroimaging studies have demonstrated abnormal brain activity during cognitive 
tasks capturing ‘motivational salience’ in CHR and psychosis. Compared to healthy controls, CHR 
subjects have been found to have hypoactivation in the ventral striatum (VS) and midbrain (11) and 
right inferior parietal lobule (12), with VS activity to ‘aberrant’ or non-salient stimuli correlating with 
severity of positive psychotic symptoms (13). Others have shown increased activation in the 
posterior cingulate cortex (PCC), middle and superior frontal gyri (MFG, SFG)(14) and ventral 
pallidum and midbrain (15). In the VS, activity while processing both non-salient (13) and salient 
stimuli (15) have been correlated with positive psychotic symptoms, as has activity in the right 
anterior insula during salient stimuli (15). In established psychosis, meta-analysis suggests 
hypoactivation of the VS (16), and individual studies have reported reduced activation in the 
cingulate and ventral tegmentum in unmedicated patients (12, 17), and in the right insula in 
medicated patients (12) while processing motivational salience.  
While the aberrant salience hypothesis of psychosis generally focuses on midbrain and striatal 
function, emerging evidence points towards a key role for other brain regions. In particular, the 
‘salience network’ (SN), anchored in the anterior cingulate (ACC) and insular cortex (IC), may play a 
role in selecting relevant internal and externally generated signals for higher order processing (18, 
19). Altered volume, activation and dysconnectivity of components of the SN have been observed 
both in established psychotic disorders (12, 20-22)  and in CHR (23-26) prior to the onset of 
psychosis, with evidence of association between symptoms and both the extent of volume loss (27) 
and altered activation (12, 28, 29) of the insula. This has led to the hypothesis that psychotic 
symptoms arise as a result of insular dysfunction within the salience network (30).  
There is evidence from healthy volunteer studies that cannabidiol (CBD), a non-psychoactive 
substance in cannabis, opposes the psychotomimetic effects of Δ9-tetrahydrocannabinol (Δ9-THC) 
(31, 32), its main psychoactive ingredient. This is complemented by evidence of efficacy as an 
antipsychotic in some (33, 34), though not all (35), clinical trials. We have recently shown that CBD 
may normalise MTL, midbrain and striatal dysfunction in CHR patients (36), but the precise 
neurocognitive mechanism of any antipsychotic effect remains unclear. Whether CBD modulates 
aberrant motivational salience, and whether this is linked to any antipsychotic effect remains 
untested.  
Therefore, in this study we investigated whether there is a pattern of abnormal activation in CHR 
compared to healthy controls during the processing of motivationally salient stimuli, and whether a 
single dose of CBD attenuates this abnormal function in CHR. We selected CHR subjects, because 
they are antipsychotic-naïve and at risk of developing psychosis (37), thus avoiding confounding 
effects of dopamine antagonism. Furthermore, they are more stable than people with established 
psychosis and can better tolerate the demands of complex neuroimaging investigations.   
We employed the monetary incentive delay task (MIDT), a reward processing task adapted for fMRI 
(38). The MIDT allows reward processing to be parsed into at least two distinct components: 
‘anticipation’ and ‘feedback’. We focused on the anticipation condition, as VS activity in this 
condition has been linked to dopamine release (39), and the SN is robustly activated in both 
anticipation of reward and loss (40). Hence, we did not limit anticipation to one specific valence (e.g. 
reward or loss), but combined all motivationally salient conditions, as previously reported (17, 41). 
Existing research in CHR using the MIDT has found abnormal activation in the PCC, MFG and SFG in 
reward anticipation (15), though abnormal striatal activity hasn’t been detected (15, 42).  
Our primary hypothesis was that CHR participants would display altered activation in the core SN (IC 
and ACC) relative to healthy controls, and a single dose of CBD would have an opposite effect in 
these regions. Our secondary hypothesis was that CHR participants would display altered activation 
in the midbrain, striatum and hippocampus, and again CBD would have an opposite effect in these 
regions. 
 
Method 
Participants 
Thirty-three CHR participants aged 18 to 35 years were recruited from early-intervention services in 
the UK. Exclusion criteria included history of psychotic or manic episode, current DSM IV diagnosis of 
substance dependence (except cannabis), neurological disorder or severe intercurrent illness, 
unwillingness to use barrier contraception, pregnancy, and any contraindication to MRI. All 
participants gave written, informed consent. Participants were required to abstain from cannabis for 
96 hours, other recreational substances for 2 weeks, alcohol for 24 hours and caffeine and nicotine 
for 6 hours before attending. Urine samples were collected prior to drug administration to monitor 
for substance use and to exclude pregnancy. 19 healthy control (HC) participants matched for age 
(within 3 years), sex and ethnicity were recruited by local advertisement. All participants gave 
written informed consent prior to commencing the trial. The study was approved by the National 
Research Ethics Service Committee of London- Camberwell St Giles. 
 
Study Design and Measures 
This study was a randomised placebo-controlled double-blind, parallel-arm fMRI investigation of the 
acute effect of 600mg oral CBD on the anticipation phase of the MIDT in subjects deemed at clinical 
high-risk of psychosis. Randomisation and blinding were carried out at the Maudsley Hospital 
Pharmacy. Psychopathology was assessed by a trained interviewer using the Comprehensive 
Assessment of At-Risk Mental States interview (CAARMS) (37) prior to drug administration. Plasma 
CBD levels were sampled 120 minutes and 300 minutes after drug administration. MRI scanning took 
place 180 minutes after drug intake. Participants were monitored for any adverse reactions. The 
study took place at the Clinical Research Facility, King’s College Hospital and the Centre for 
Neuroimaging Sciences, Department of Neuroimaging, Institute of Psychiatry, Psychology, and 
Neuroscience.  
 
Monetary incentive delay task 
Participants underwent two runs of the MIDT each consisting of 48 individual trials. Four conditions 
were used, induced by learned visual cues: neutral (£0), win small (£0.20), win large (£2.00) and lose 
(£2). Participants underwent standardised training prior to entering the scanner. There were 12 
trials for each condition randomised into 48 trials per run, with two consecutive runs lasting 8 
minutes each. Participants began each run with a baseline figure of £10.00 and received payment at 
the end of the same study day for the cumulative total won in both runs.  
The cue was presented for 250ms and the feedback for 1450ms (see Supplementary Fig 1). Target 
presentation time varied for each run by +/-10ms from an initial 250ms and ranging between 150ms 
to 300ms to assure approximately 66% success for each participant. A successful hit depended on 
the participant responding by pressing the button during target presentation. A response prior to 
100ms after target onset was considered an unsuccessful ‘false-start’. Scanning of anticipation 
occurred during the interval between cue and target which varied from 3700 to 4500ms in duration. 
The inter-trial interval was 10s for all trials. 
 
Drug Intervention 
CHR participants were randomised to receive either oral 600mg CBD (CHR-CBD; CBD obtained from 
THC Pharm, Germany) or placebo (CHR-PLB) prepared in identical capsules following a standard light 
breakfast. Participants were administered the capsule at approximately 11am, 180 minutes before 
the start of scanning.  
 
Scanning Parameters 
Participants underwent structural and functional MRI in a single session. Images were acquired using 
a General Electric Signa HDx 3.0T MRI scanner. Structural images were acquired using a whole-brain 
sagittal T1-weighted scan based on Alzheimer’s Disease Neuroimaging Initiative parameters (TE=2.85 
ms, TR = 6.98ms, inversion time=400ms, flip angle=110, voxel size 1.0 x 1.0 x 1.2mm). 480 T2*-
weighted images were acquired in two 8-minute runs (TE=30ms, TR=2.0s, flip angle=75°, 39 x 3mm 
thick axial planes, 3.3mm inter-slice gap, in-plane voxel size 3.75 x 3.75mm).  
 
Analysis 
Imaging 
fMRI data were preprocessed using SPM8 (Wellcome Trust Centre for Neuroimaging) by realignment 
of functional images, co-registration with the structural scan, spatial normalization into standard 
MNI space and smoothing by a Gaussian filter (FWHM=8 mm). Using general linear model regression 
with factors time-locked to task events and convolved with a canonical hemodynamic response 
function, the regression coefficient (b-value) for each voxel was determined. There were 12 
regressors in the task design: 4 modelling conditions of anticipation (anticipation win large £2, 
anticipation win small 20p, anticipation lose £2 and anticipation neutral), 7 modelling feedback 
conditions (neutral feedback following anticipation neutral and successful or unsuccessful response 
feedback for the remaining 6 anticipation conditions) and 1 regressor modelling response activity for 
all 4 anticipation conditions. Within-group maps were created for salience condition by combining 
anticipation of all win and loss conditions and contrasting with neutral anticipation. Between-group 
contrasts were created comparing HC with CHR-PLB (HC-vs-CHR-PLB) and CHR-PLB with CHR-CBD 
(CHR-PLB-vs-CHR-CBD).  
Two region-of-interest (ROI) analyses were performed using masks created for the SN and combined 
hippocampus-midbrain-striatum (HMS). The SN mask was created using the Pick Atlas in SPM8 by 
selecting human bilateral ACC and insulae. The HMS mask was defined by a previous study of CHR 
(7) and consisted of bilateral medial hippocampi, subicula, caudate, putamen, pallidum and 
midbrain. Exploratory whole-brain analysis was also conducted.  
To test the hypothesis that activation in CHR-CBD would be intermediate between that of HC and 
CHR-PLB, we examined whether a linear relationship in brain activation (CHR-PLB>CHR-CBD>HC) 
existed within the ROI’s and at whole brain level by 3-way ANOVA. We applied a family-wise error 
corrected (FWE) p<0.05 threshold, corrected for volume for all analyses. 
 
Behavioural Performance 
Behavioural performance was analysed for the two between-group contrasts of interest (HC-vs-CHR-
PLB and CHR-PLB-vs-CHR-CBD), including five components: mean monetary reward (£GBP), accuracy 
(% response on target), reaction time (ms), false-starts (premature action initiation) and any trial 
responses (attention, %). 
Pairwise independent t-testing was applied for mean monetary reward, pairwise ANOVA for mean 
reaction time, and pairwise binary logistic regression for accuracy, false-starts, delayed reaction and 
any trial response. 
We tested for correlation between activation and behavioural performance (RT) and psychotic 
symptoms using the mean b-value for ANOVA-derived clusters. 
 
Results 
There was no significant difference between HC (n=19), CHR-PLB (n=17) and CHR-CBD (n=16) in age, 
gender, ethnicity, country of birth or handedness (see Table 1). There were no significant differences 
between CHR-PLB and CHR-CBD in either positive or negative symptom subscale of the CAARMS or 
in terms of current tobacco smoking and cannabis use. HC participants were selected to have 
minimal drug use history. In the CHR-CBD group, mean plasma CBD levels were 126.4nM (sd 221.8) 
before and 823.0nM (sd 881.5) after the fMRI scan. 
TABLE 1 
 
Behavioural performance 
Mean monetary reward: at the end of the 96 trials (2 runs of 48), the HC group appeared to win a 
higher cumulative total of money, though this was non-significant in pairwise analysis.  
TABLE 2 
Accuracy: There was a significant likelihood of increased accuracy in the salience condition 
compared to neutral in both HC-vs-CHR-PLB (p<0.001) and CHR-PLB-vs-CHR-CBD (p<0.001). There 
was a trend toward impaired accuracy in CHR-PLB compared to HC across all stimuli conditions 
(p=0.085), but there was no interaction between salience and group. There was no significant 
difference between CHR-PLB and CHR-CBD or group by condition interaction. 
Reaction time (see Figure 1): RT shortened significantly in the salience condition compared to the 
neutral stimuli condition for both HC-vs-CHR-PLB (p<0.001) and CHR-PLB-vs-CHR-CBD (p<0.001). 
Regarding HC-vs-CHR-PLB, there was a trend-level interaction between group and condition 
(p=0.085) such that the acceleration of response (as indexed by shorter RT) while viewing salient 
stimuli compared to neutral stimuli was greater in HC than in CHR-PLB. RT was significantly slower 
overall in CHR-CBD than CHR-PLB (p<0.001). 
FIGURE 1 
 
False-starts (premature action initiation): CHR-PLB were significantly more likely to produce false-
starts than HC (p<0.001) and CHR-CBD at trend-level (p=0.064). There were no significant effects of 
condition or group by condition interaction in either HC-vs-CHR-PLB or CHR-PLB-vs-CHR-CBD. 
Trial response: in both pairwise analyses, subjects were more likely to respond in the salience 
condition (HC-vs-CHR-PLB p<0.001; CHR-PLB-vs-CHR-CBD p<0.001). There was no difference 
between CHR-PLB and HC, but CHR-CBD was significantly less likely to respond than CHR-PLB 
(p<0.001). There was no group by condition interaction in either HC-vs-CHR-PLB or CHR-PLB-vs-CHR-
CBD. 
Imaging 
A single participant in the CBD group was excluded from imaging analysis because of inattention to 
all neutral trials with a subsequent lack of corresponding contrasts, such that the imaging sample 
sizes were 19 (HC), 15 (CHR-CBD) and 17 (CHR-PLB).  
 
Task network (HC only) 
In HC, salience condition was associated with activation in both SN and HMS masks and across the 
whole brain (see supplementary Table 1). 
 
HC-vs-CHR-PLB 
Within the SN (Table 3, Figure 2), the bilateral frontal operculae (FO; left: k=12 voxels, T=4.77, 
p=0.002; right: k=18 voxels, T=4.47, p=0.006) and the left insula converging with left parietal 
operculum (PO; k=13 voxels, T=4.11, p=0.019) were significantly more active in CHR-PLB compared 
to HC during salient compared to neutral condition. No areas met significance threshold for HMS. At 
wholebrain level (Supplementary Table 2, Figure 2), the following regions were significantly more 
active in CHR-PLB: the left SFG medial part (k=141 voxels, T=6.55, p<0.001), a cluster spanning the 
left inferior frontal gyrus opercular part and left FO (T=5.47, p=0.002; T=5.26, p=0.004), and the left 
superior temporal gyrus (k=13 voxels, T=5.06, p=0.009).  
TABLE 3 
FIGURE 2 
 
CHR-PLB-vs-CHR-CBD 
Within the SN (Table 3, Figure 2), the left insula/claustrum (k=3 voxels, T=3.98, p=0.035) was more 
active in CHR-PLB compared to CHR-CBD during salient relative to neutral condition. No areas met 
significance threshold for HMS. At wholebrain level (Supplementary Table 2, Figure 2), the right SFG 
lateral part was more active in CHR-PLB (k=3 voxels, T=4.99, p=0.025), and the right cerebellum 
posterior lobe was more active in CHR-CBD (k=6 voxels, T=5.03, p=0.022). 
 
Between-group linear analysis 
ANOVA of the SN (CHR-PLB>CHR-CBD>HC; Table 3, Figure 2) during salient relative neutral condition 
generated two significant peaks. The largest was located in the left insula/PO (k=26 voxels, F=20.13, 
p=0.009) with the exact same peak coordinate reported in HC-vs-CHR-PLB (-32, -16, 22). The second 
was located in the left FO (k=6 voxels, F=20.65, p=0.007). Mean b-values for each group confirmed 
increased activation in CHR-PLB compared to HC, with CHR-CBD intermediate. No areas met 
significance threshold for HMS. Exploratory wholebrain ANOVA (CHR-PLB>CHR-CBD>HC; 
Supplementary Table 2, Fig 2), generated a significant peak in the left SFG medial part close to the 
HC-vs-CHR-PLB peak (-10, 22, 58, k=18 voxels, F=27.56, p=0.006). Mean b-values again confirmed 
increased activation in PLB relative to HC, with CBD to be intermediate. 
 
Relationship between behavioural performance and imaging 
Within the SN, there was a negative correlation with activity in the left insula/PO in HC (r=-0.503, 
p<0.001, CI=-0.737 to 0.270; Figure 2), which was absent in CHR. In CHR-PLB, there was a negative 
correlation between the b-values and mean RT difference between salience and neutral conditions 
(r=-0.308, p=0.028, CI=-0.581 to -0.034; Figure 2), which was absent in CHR-CBD. Please see 
Supplementary Analysis for wholebrain. 
 
Relationship between psychopathology and imaging 
Within the SN, there was a positive correlation (r=0.569, p= 0.017, CI=0.117 to 1.022) between 
CAARMS positive score in CHR-PLB and left insula/PO activation (Figure 2). 
 
Discussion 
In this study, we investigated differences in brain function and behaviour between healthy controls 
and CHR subjects and examined the effect of a single dose of CBD relative to placebo condition in 
CHR subjects while processing motivationally salient stimuli. We confirmed our primary hypothesis 
of abnormal activation within the salience network in CHR-PLB compared to HC, which was 
modulated by a single dose of CBD. Compared to HC, CHR-PLB had increased activation in the left 
insula/PO and bilateral FO, associated with premature action initiation. CBD appeared to attenuate 
activation in the proximate left insula/claustrum, associated with an overall slowing of reaction time. 
We also established a linear relationship in activation of the left insula/PO and left FO between CHR-
PLB, CHR-CBD and HC, with activation intermediate in CHR-CBD. However, we found no differences 
in activation in the hippocampus-midbrain-striatum between either HC and CHR-PLB or CHR-PLB and 
CHR-CBD. 
Shorter RT during salient compared to neutral stimuli across all groups is consistent with previous 
literature (43) and indicates that RT acceleration during the MIDT may be an index of salience 
perception. In HC, left insula/PO activity negatively correlated with RT during salient stimuli. This 
may indicate that insular activation is a proxy measure of salience perception and is consistent with 
the idea that the insula detects salient stimuli to guide behaviour (18). Such a relationship was 
absent in the CHR-PLB group. In contrast, activation at this site in CHR-PLB negatively correlated with 
the RT acceleration during salient compared to neutral stimuli (as indexed by mean RT difference 
between neutral and salience conditions), indicating that the higher the insular activation, the 
slower was the acceleration. This may imply that greater insular activation in CHR-PLB relative to HC 
was associated impaired discrimination of salience in CHR patients and could be a marker of 
aberrant motivational salience processing. Furthermore, activation at this site positively correlated 
with CAARMS positive symptoms in CHR-PLB, directly linking aberrant motivational salience 
processing with psychopathology.  
The left insula/PO site of abnormal activation is posteriorly situated and overlaps with the primary 
site of somatosensory interoceptive input, relaying information to the anterior insula for higher 
order processing (19) and switching between the default and central executive networks (44, 45). 
Left insula function has been implicated in both the generation of psychotic symptoms (28, 29, 46) 
and in antipsychotic treatment (28, 47). Our results extend previous literature by showing that 
increased activation within the SN was associated with both aberrant processing of motivationally 
salient stimuli and psychotic symptoms in patients in the very early stages of psychosis. A single dose 
of CBD attenuated activation in this region, such that it was intermediate between CHR-PLB and HC. 
However, CBD did not have any effect on striatal or MTL function in the present study, unlike our 
previous report (36). This may reflect the different cognitive activation tasks used in the two studies, 
as in our previous study, we employed a verbal learning task. Here, we did not identify altered 
striatal or MTL function in CHR-PLB when compared to HC, and a lack of CBD effect may be a 
consequence. It has been suggested that while the striatum is involved in attribution of motivational 
salience to stimuli (1), the insula may be involved with ‘proximal salience’, thought to involve the 
evaluation of stimuli (30). Previous studies in CHR patients did not detect any evidence of altered 
striatal activity (15, 42), consistent with absence of altered striatal activation during the anticipation 
of motivationally salient stimuli in CHR-PLB relative to HC here. Whether the lack of an effect of 
diagnosis (CHR-PLB vs HC contrast) or treatment (CBD) on striatal function in the present study 
reflects a specific dysfunction in ‘proximal salience’, as opposed to motivational salience, and a 
specific CBD effect on the former, remains to be tested.  
The precise molecular mechanism of action of CBD remains unclear. There is evidence that CBD may 
be a negative allosteric modulator at the CB1 receptor (48). As CB1 is a presynaptic G-protein 
coupled inhibitory receptor, CBD could promote neurotransmitter release by inhibiting presynaptic 
agonism induced by retrograde endocannabinoid messengers. CBD may also enhance 
endocannabinoid tone by inhibiting breakdown of the CB1 agonist anandamide by fatty acid amide 
hydrolase (49). In light of evidence of CB1 receptor alteration in the insula in schizophrenia (50, 51), 
any antipsychotic effect of CBD may also be through modulation of endocannabinoid dysfunction 
within the insula.   
 
Limitations 
The present results should be considered in light of certain limitations. Using a within-subject, 
repeated measures design would have been ideal instead of the cross-sectional design that we have 
employed, as that would have allowed us to directly test whether CBD normalised altered insular 
function in CHR patients. Logistical complexities of carrying out such a study influenced our design 
choice. It is also worth noting that the CHR and HC groups differed in terms of years in education, 
current cannabis and other drug use that may have influenced brain activation differences between 
the two groups.  
 
Conclusion 
In summary, results presented here suggest that altered function of the insular cortex, a core 
component of the salience network, may underlie aberrant salience processing and psychotic 
symptoms in patients at clinical high-risk of psychosis and that a single dose of CBD may attenuate 
some of this dysfunction. Future studies need to investigate whether such effects may underlie the 
antipsychotic effects of CBD observed following a period of treatment.. 
 
 
Supplementary information is available at MP’s website. 
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Tables 
 
Table 1. Sample characteristics. 
 
 HC (n=19) CHR-CBD 
(n=16) 
CHR-PLB 
(n=17) 
Pairwise analysis 
HC-vs-CHR-
PLB 
CHR-PLB-vs-
CHR-CBD 
Age/yr (sd) 23.9 
(4.15) 
22.7 
(5.08) 
24.1 (4.48) p=0.91 1
 
p=0.42 1 
Ethnicity % White 57.9 62.5 41.2 p=0.59 
 
p=0.43 2 
Black 26.3 12.5 29.4 
Asian 0 0 5.9
Mixed 15.8 25 23.5 
UK born % 57.9 68.8 82.4 p=0.26 2 
 
p=0.51 2 
Years education (sd) 17.0 
(1.58) 
14.5 
(3.06) 
11.9 (3.44) P<0.01 1  
 
p=0.09 1 
Gender % (male) 57.9 62.5 41.2 p=0.32 2 
 
p=0.22 2 
UDS % (positive) 
 
THC 
Morphine 
Benzodiazepine 
Phencyclidine 
Missing 
0 
 
0 
0 
0 
0 
0 
63 
 
13 
6 
0 
0 
19 
47 
 
29 
0 
6 
6 
12 
Not 
compared 3 
 
p=0.45 2 
Current smoker % (yes) 10.5 31.3 56.3 Not 
compared 3 
p=0.14 2 
Current cannabis use % 0 43.8 41.2 Not 
compared 3 
p=0.88 2 
Handedness % (right) 94.7 87.5 100 p=0.38 2 
 
p=0.16 2 
CAARMS score (sd) 
Positive symptoms NA 40.19 
(20.79) 
42.94 
(29.46) 
NA p=0.75 1 
Negative symptoms NA 23.25 
(16.49) 
28.41 
(10.17) 
NA p=0.43 1 
Table 1. Sample characteristics. Abbreviations: HC=healthy control group, CHR-CBD=clinical-high risk 
cannabidiol group, CHR-PLB=clinical-high risk placebo group, CAARMS=Comprehensive Assessment 
of At-Risk Mental State. 1Independent t-test, 2Pearson chi-squared test, 3HC were selected to have 
minimal drug use and hence were not compared with CHR participants on these parameters 
 
 
 
 
 
Table 2. Behavioural performance. 
 HC CHR-CBD CHR-PLB Pairwise analysis 
HC-vs-CHR-
PLB 
HC-vs-CHR-
PLB 
Mean monetary reward 
£GBP (SD) 
41.00 
(6.63) 
37.48 
(12.14) 
36.13 
(11.97) 
p=0.150 1 p=0.751 1 
Accuracy (successful hits on target) % 
Overall 63.5 60.4 59.3 Group 
exp(B)=1.147 (CI 
0.981-1.341), 
p=0.085 2  
 
Condition 
exp(B)=0.639 (CI 
0.546-0.747), 
p<0.001 2 
 
Condition*group 
exp(B)=0.841 (CI 
0.615-1.149), 
p=0.276 2 
Group 
exp(B)=0.985 (CI 
0.837-1.159), 
p=0.855 2 
 
Condition 
exp(B)=0.616 (CI 
0.0.523-0.724), 
p<0.001 2 
 
Condition*group 
exp(B)= 0.780 (CI 
0.564-1.080), 
p=0.134 2 
Neutral  53.9 49.2 52.7 
Salience 66.7 64.1 61.5 
Mean reaction time/ms >100ms (SD) 
Overall 243.13 
(44.97) 
251.31 
(52.19) 
245.70 
(46.82) 
Group
F(1,3275)=0.207, 
p=0.649 3 
 
Condition 
F(1,3275)=36.60, 
p<0.001 3 
 
Condition*group 
F(1,3275)=2.974, 
p=0.085 3 
Group 
F(1,3151)=16.67, 
p<0.001 3 
 
Condition 
F(1,3151)=51.500, 
p<0.001 3 
 
Condition *group 
F(1,3151)=0.000, 
p=0.992 3 
Neutral 254.32 
(49.36) 
262.68 
(58.60) 
251.93 
(52.02) 
Salience  239.69 
(42.97) 
248.00 
(49.72) 
243.79 
(44.96) 
False starts % 
Overall 0.9 1.8 3.2 Group 
exp(B)=4.630, (CI 
2.054-10.437), 
p<0.001 2 
 
Condition 
exp(B)=1.446 (CI 
0.642-3.260), 
p=0.374 2 
 
Condition*group 
exp(B)=2.224 (CI 
0.438-11.303), 
Group 
exp(B)=1.678 (CI 
0.970-2.902), 
p=0.064 2 
 
Condition 
exp(B)=0.875 (CI 
0.506-1.513), 
p=0.632 2 
 
Condition*group 
exp(B)= 0.814 (CI 
0.272-2.435), 
Neutral 0.5 2.2 3.2
Salience  1.0 1.7 3.1
p=0.335 2 p=0.712 2 
Delayed response % 
Overall 33.2 32.8 35.0 Group 
exp(B)=0.995, (CI 
0.843-1.175), 
p=0.953 2 
 
Condition 
exp(B)=0.733 (CI 
0.621-0.866, 
p<0.001 2 
 
Condition*group 
exp(B)=0.816 (CI 
0.585-1.139), 
p=0.232 2 
Group 
exp(B)=1.035 (CI 
0.867-1.235), 
p=0.704 2 
 
Condition 
exp(B)=0.747 (CI 
0.626-0.892), 
p=0.001 2 
 
Condition*group 
exp(B)=0.848 (CI 
0.595-1.208), 
p=0.362 2 
Neutral 40.3 39.6 38.8 
Salience 31.0 30.8 33.9
Trial response % 
Overall 96.8 93.0 96.6 Group 
exp(B)=0.939, (CI 
0.624-1.415), 
p=0.765 2 
 
Condition 
exp(B)=7.667 (CI 
5.092-11.546), 
p<0.001 2 
 
Condition*group 
exp(B)=0.810 (CI 
0.488-2.507), 
p=0.810 2 
Group 
exp(B)=2.330 (CI 
1.635-3.321), 
p<0.001 2 
 
Condition 
exp(B)=5.754 (CI 
4.037-8.202), 
p<0.001 2 
 
Condition*group 
exp(B)=0.623 (CI 
0.307-1.265), 
p=0.190 2 
Neutral 90.8 84.1 90.7 
Salience 98.8 96.0 98.6
Table 2. Behavioural performance. Abbreviations: HC=healthy control group, CHR-CBD=clinical-high 
risk cannabidiol group, CHR-PLB=clinical-high risk placebo group. 1 Independent t-test, 2 Pairwise 
binary logistic regression, 3 Analysis of variance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Salience network analysis for salience-vs-neutral contrast. 
 
Region Peak coordinate 
(MNI) 
Cluster size p 
x y z 
Pairwise comparison 
CHR-PLB>HC 
Left frontal operculum -42 14 12 12 0.002 
Right frontal operculum 42 14 12 18 0.006 
Left insula/parietal operculum -32 -16 22 13 0.019 
Pairwise comparison 
CHR-PLB>CHR-CBD 
Left insula/claustrum -30 -16 20 3 0.035 
3-way ANOVA  
CHR-PLB>CHR-CBD>HC 
Left frontal operculum -42 14 22 6 0.007 
Left insula/parietal operculum -32 -16 22 26 0.009 
Table 3. Salience network analysis for salience-vs-neutral contrast. Small volume corrected, family 
wise error-corrected p<0.05, k≥3voxels. Abbreviations: HC=healthy control group, CHR-CBD=clinical-
high risk cannabidiol group, CHR-PLB=clinical-high risk placebo group. 
 
 
Figure 1. Mean reaction time by condition by group 
 
 
 
 
Figure 2. Salience network region-of-interest analysis of salience>neutral contrast 
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 Figure 2. Salience network region-of-interest analysis of salience>neutral contrast (small-volume corrected, p<0.05 FWE-corrected at voxel level, k≥3 
voxels). (A) Pairwise comparison CHR-PLB>HC with clusters in bilateral frontal operculae and left insula/parietal operculum. (B) Pairwise comparison CHR-
PLB>CHR-CBD with cluster in left insula/claustrum. (C) 3-way ANOVA CHR-PLB>CHR-CBD>HC with clusters in left frontal operculum and left insula/parietal 
operculum. (D) Mean b-value parameter estimates extracted from the 2 clusters generated by ANOVA for each group (CHR-PLB, CHR-CBD, and HC) showing 
increased activation in CHR-PLB relative to HC with CHR-CBD intermediate in the left frontal operculum and left insula/parietal operculum. (E) Negative 
correlation between mean b-value from ANOVA-derived cluster of left insula/parietal operculum and mean reaction time for salience condition in HC. (F) 
Positive correlation between mean b-value from ANOVA-derived cluster of left insula/parietal operculum and CAARMS positive subscale in CHR-PLB. (G) 
Negative correlation between mean b-value from ANOVA-derived cluster of left insula/parietal operculum and difference in mean reaction time between 
neutral and salience condition in CHR-PLB. 
 
 
 
